XML 52 R32.htm IDEA: XBRL DOCUMENT
v3.23.4

Related Parties Transactions (Tables) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2023 | Dec. 31, 2022
Related Parties Transactions [Abstract] |  |
Schedule of Related Parties of the Company with whom Transactions | The related parties of the company with whom transactions are reported in these financial statements are as follows:
Name of entity or Individual |  | Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”) |  | Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”) |  | 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”) |  | Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang
YuanGene Corporation (the “YuanGene”) |  | Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the “AsiaGene”) |  | Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang |  | Former President and Chairman
Keypoint Technology Ltd. (the “Keypoint’) |  | The Chairman of Keypoint is Eugene Jiang’s mother.
Lion Arts Promotion Inc. (the “Lion Arts”) |  | Shareholder of the Company
Yoshinobu Odaira (the “Odaira”) |  | Director of the Company
GenePharm Inc. (the “GenePharm”) |  | Dr. George Lee, Board Director of BioKey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”) |  | Shareholder of the Company
LBG USA, Inc. (the “LBG USA”) |  | 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the “LionGene”) |  | Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the “Kimho”) |  | Shareholder of the Company
The Jiangs |  | Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company; the Chairman of Rgene; the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company. Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Amkey Ventures, LLC (“Amkey”) |  | An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc
BioLite Japan |  | Entity controlled by controlling beneficiary shareholder of ABVC
BioHopeKing Corporation |  | Entity controlled by controlling beneficiary shareholder of ABVC
ABVC BioPharma (HK), Limited |  | An entity 100% owned by Mr. Tsung-Shann Jiang
| The related parties of the company with whom transactions are reported in these financial statements are as follows:
Name of entity or Individual |  | Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”) |  | Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”) |  | 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”) |  | Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene
YuanGene Corporation (the “YuanGene”) |  | Controlling beneficiary shareholder of the Company
AsiaGene Corporation (the “AsiaGene”) |  | Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene
Eugene Jiang |  | Former President and Chairman
Keypoint Technology Ltd. (the “Keypoint’) |  | The Chairman of Keypoint is Eugene Jiang’s mother.
Lion Arts Promotion Inc. (the “Lion Arts”) |  | Shareholder of the Company
Yoshinobu Odaira (the “Odaira”) |  | Director of the Company
GenePharm Inc. (the “GenePharm”) |  | Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.
Euro-Asia Investment & Finance Corp Ltd. (the “Euro-Asia”) |  | Shareholder of the Company
LBG USA, Inc. (the “LBG USA”) |  | 100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
LionGene Corporation (the “LionGene”) |  | Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene
Kimho Consultants Co., Ltd. (the “Kimho”) |  | Shareholder of the Company
The Jiangs |  | Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company. Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
Amkey Ventures, LLC (“Amkey”) |  | An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc
BioLite Japan |  | Entity controlled by controlling beneficiary shareholder of ABVC
BioHopeKing Corporation |  | Entity controlled by controlling beneficiary shareholder of ABVC
ABVC BioPharma (HK), Limited |  | An entity 100% owned by Mr. Tsung-Shann Jiang
Schedule of Accounts Receivable Due from Related Parties | Accounts receivable due from related parties consisted of the following as of the periods indicated:
|  | September 30, |  |  | December 31, |
|  | 2023 |  |  | 2022 |
|  | (Unaudited) |  |  |  |
GenePharm Inc. |  | $ | - |  |  | $ | 142,225 |
Rgene |  |  | 624,373 |  |  |  | 615,118 |
Total |  | $ | 624,373 |  |  | $ | 757,343 |
| Accounts receivable due from related parties consisted of the following as of the periods indicated:
|  | December 31, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
GenePharm Inc. |  | $ | 142,225 |  |  | $ | 142,225 |
Rgene |  |  | 615,118 |  |  |  | 2,374 |
Amkey |  |  | - |  |  |  | 800 |
Total |  | $ | 757,343 |  |  | $ | 145,399 |
Schedule of Revenue Due from Related Parties | Revenue due from related parties consisted of the following as of the periods indicated:
|  | September 30, |  |  | September 30, |
|  | 2023 |  |  | 2022 |
|  | (Unaudited) |  |  | (Unaudited) |
Rgene |  | $ | 1,900 |  |  | $ | 307,788 |
Total |  | $ | 1,900 |  |  | $ | 307,788 |
Schedule of Due from Related Parties - Current | Due from related–party - Current
|  | September 30, |  |  | December 31, |
|  | 2023 |  |  | 2022 |
|  | (Unaudited) |  |  |  |
Rgene |  | $ | 535,046 |  |  | $ | 513,819 |
Total |  | $ | 535,046 |  |  | $ | 513,819 |
| Due from related party- Current
|  | December 31, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
Rgene |  | $ | 513,819 |  |  | $ | - |
Total |  | $ | 513,819 |  |  | $ | - |
Schedule of Due from Related Parties - Non Current | Due from related parties – Non-Current
|  | September 30, |  |  | December 31, |
|  | 2023 |  |  | 2022 |
|  | (Unaudited) |  |  |  |
BioFirst (Australia) |  | $ | 822,781 |  |  | $ | 752,655 |
BioHopeKing Corporation |  |  | 107,615 |  |  |  | 112,822 |
Total |  | $ | 930,396 |  |  | $ | 865,477 |
| Due from related parties- Noncurrent
|  | December 31, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
Rgene |  | $ | - |  |  | $ | 49,110 |
BioFirst (Australia) |  |  | 1,028,556 |  |  |  | 491,816 |
BioHopeKing Corporation |  |  | 112,822 |  |  |  | 124,972 |
LBG USA |  |  | - |  |  |  | 675 |
BioLite Japan |  |  | - |  |  |  | 150,000 |
Keypoint |  |  | - |  |  |  | 1,610 |
Total |  | $ | 1,141,378 |  |  | $ | 818,183 |
Schedule of Amount Due to Related Parties | Amount due to related parties consisted of the following as of the periods indicated:
|  | September 30, |  |  | December 31, |
|  | 2023 |  |  | 2022 |
|  | (Unaudited) |  |  |  |
BioFirst Corporation |  | $ | 315,947 |  |  | $ | 188,753 |
The Jiangs |  |  | 19,789 |  |  |  | 19,789 |
Due to shareholders |  |  | 144,460 |  |  |  | 151,450 |
Total |  | $ | 480,196 |  |  | $ | 359,992 |
| Amount due to related parties consisted of the following as of the periods indicated:
|  | December 31, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
BioFirst Corporation |  | $ | 188,753 |  |  | $ | 40,878 |
BioFirst (Australia) |  |  | 275,901 |  |  |  | 132,443 |
AsiaGene |  |  | - |  |  |  | 24,017 |
YuanGene |  |  | - |  |  |  | 9,205 |
The Jiangs |  |  | 19,789 |  |  |  | 18,750 |
Due to shareholders |  |  | 151,450 |  |  |  | 168,131 |
Total |  | $ | 635,893 |  |  | $ | 393,424 |
Schedule of Revenue from Related Party |  | Revenue from related party
|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |
Rgene |  | $ | 904,043 |  |  | $ | 2,373 |
Total |  | $ | 904,043 |  |  | $ | 2,373 |

X
- References No definition available. + Details
Name: | abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock
Namespace Prefix: | abvc_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of related party transactions. Amount due to related party. + References No definition available. + Details
Name: | abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty
Namespace Prefix: | abvc_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information revenue due from related party. + References No definition available. + Details
Name: | abvc_ScheduleOfRevenueDueFromRelatedPartyTextBlock
Namespace Prefix: | abvc_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of Revenue from related party. + References No definition available. + Details
Name: | abvc_ScheduleOfRevenueFromRelatedPartyTableTextBlock
Namespace Prefix: | abvc_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3,4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + References No definition available. + Details
Name: | us-gaap_ScheduleOfDebtTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates. + References No definition available. + Details
Name: | us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration